Pneumococcal pneumonia is a serious disease with considerable morbidity and mortality in the elderly. Despite adequate antibiotic treatment, the long-term mortality of pneumococcal pneumonia remains high. Preventive measures in the form of vaccination, therefore, are warranted. Twenty-three-valent polysaccharide vaccines have a broad coverage but limited efficacy. Pneumococcal conjugate vaccines have been shown in children to be able to prevent invasive and mucosal pneumococcal diseases. It should be realized that the serotype composition of current pneumococcal conjugate vaccines is not tailored for the elderly, and that replacement disease can occur. Yet, the current 13-valent conjugate vaccine has been shown to protect against infections with vaccine serotypes. Long-term mortality of pneumococcal pneumonia should be included in policy making about the introduction of these vaccines for the elderly.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881283PMC
http://dx.doi.org/10.2147/RMHP.S130405DOI Listing

Publication Analysis

Top Keywords

pneumococcal pneumonia
12
polysaccharide vaccines
8
vaccines elderly
8
long-term mortality
8
mortality pneumococcal
8
pneumococcal conjugate
8
conjugate vaccines
8
pneumococcal
7
vaccines
5
triptych hermit
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!